Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.Please see the attached notification form for further information. Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 936 32 966 E-mail: [email protected] This information is subject to the disclosure requirements in the Market Abuse Regulation EU...
Comunicato Precedente
Comunicato Successivo
Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.
Please see the attached notification form for further information.
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: [email protected]
This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.
Attachment
- PDMR notification form - Bomi Framroze Holding AS
Per maggiori informazioni
Sito Web
h-bc.no
Ufficio Stampa
Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
;




